SCHEMBL40175

SCHEMBL40175

O=C(CBr)c1cccc(C(F)(F)F)c1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.65
GSK3B P49841 3/20 0.62
PTPN1 P18031 2/20 0.62
SRD5A2 P31213 1/20 0.54
CTNNB1 P35222 1/20 0.54
WNT3A P56704 1/20 0.54
POLB P06746 2/20 0.53
ALDH1A1 P00352 1/20 0.53
ACHE P22303 1/20 0.51
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
P2RX1 P51575 1/20 0.51
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.49
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29742875 1.00 CES2 (0.65) CES2GSK3BPTPN1SRD5A2CTNNB1
SCHEMBL10612843 0.92 CES2 (0.56) CES2GSK3BPTPN1SRD5A2CTNNB1
SCHEMBL31557727 0.88 CES2 (0.62) CES2SRD5A2CTNNB1WNT3APOLB
SCHEMBL30758861 0.85 CES2 (0.69) CES2SRD5A2CTNNB1WNT3APOLB
SCHEMBL2073691 0.84 ACHE (0.72) CES2SRD5A2CTNNB1WNT3APOLB
SCHEMBL1712437 0.84 CES2 (0.67) CES2SRD5A2CTNNB1WNT3APOLB
SCHEMBL1725346 0.82 ACHE (0.53) CES2GSK3BPTPN1CTNNB1WNT3A
SCHEMBL23243879 0.82 GSK3B (0.63) CES2GSK3BPTPN1
SCHEMBL13774627 0.82 PTPN1 (0.63) CES2GSK3BPTPN1ALDH1A1KMT2A
SCHEMBL10274701 0.82 CES2 (0.65) CES2SRD5A2CTNNB1WNT3APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1939887-A Process for preparation of optionally substituted trifluoromethyl phenacyl bromide SALTIGO GMBH (DE) 2007-04-04 CN claimed
EP-1752438-A2 Process for preparation of optionally substituted trifluoromethyl phenacyl bromide Saltigo GmbH (DE) 2007-02-14 EP claimed
EP-0138716-B1 2-TOLYL-MORPHOLINE DERIVATIVES FOR THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-08-12 EP claimed
EP-3599854-B1 PYRROLIDINONES AND A PROCESS TO PREPARE THEM FMC CORP (US) 2026-05-06 EP disclosed
US-20260092063-A1 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2026-04-02 US disclosed
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-12-25 US disclosed
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 US disclosed
EP-4556476-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2025-05-21 EP disclosed
US-12304912-B2 Fused bicyclic RAF inhibitors and methods for use thereof JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2025-05-20 US disclosed
WO-2025021943-A1 QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS NEURALIS (BE) 2025-01-30 WO disclosed
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF PRISM MEDICINES, INC. 2025-01-09 US disclosed
US-4024273-A Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity SMITHKLINE CORPORATION (US) 1977-05-17 US disclosed
US-4013692-A ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS RIKER LABORATORIES, INC. (US) 1977-03-22 US disclosed
US-4005212-A ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE RHONE-POULENC S.A. (FR) 1977-01-25 US disclosed
US-3997557-A ANTIARRHYTHMIA, CNS DEPRESSANT, ANTIINFLAMMATORY, HYPOTENSIVE AMERICAN HOECHST CORPORATION (US) 1976-12-14 US disclosed
US-3991076-A Aminoalkylthiopyranopyrroles AMERICAN HOECHST CORPORATION (US) 1976-11-09 US disclosed
US-3975537-A SUBSTITUTED BENZOFURANS SMITH KLINE (US) 1976-08-17 US disclosed
US-3965181-A Tricyclic pharmacological agents, intermediates and methods of making SYNTEX (U.S.A.) INC. (US) 1976-06-22 US disclosed
US-3947470-A CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS SMITHKLINE CORPORATION (US) 1976-03-30 US disclosed
US-3931407-A ANTIINFLAMMATORY, ANALGESIC AMERICAN HOECHST CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 CES2 941/4885GSK3B 3183/4885PTPN1 1910/4885
US-12304912-B2 Fused bicyclic RAF inhibitors and methods for use thereof BRAF, RAF1, NRAS CES2 4215/4885GSK3B 212/4885PTPN1 1407/4885
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS EIF2B1, EIF4EBP1, EIF2B3 CES2 2186/4885GSK3B 2187/4885PTPN1 4537/4885
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF GBA1, PIKFYVE, MAN2B1 CES2 1314/4885GSK3B 3174/4885PTPN1 862/4885
US-20260092063-A1 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF BRAF, NRAS, RAF1 CES2 4576/4885GSK3B 83/4885PTPN1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.